House Dust Mite Allergy Clinical Trial
Official title:
Role of the Central Nervous System in Allergic Rhinitis: Activation of Different Brain Regions After a Nasal Histamine Provocation in Healthy and Allergic Patients
In order to evaluate the effects a nasal provocation on the activation of different brain regions, the investigators want to set up a clinical trial investigating the short-term effects of a nasal histamine provocation in healthy volunteers and allergic patients while in supine position under the functional MRI device in order to visualize different brain regions.
Status | Terminated |
Enrollment | 14 |
Est. completion date | March 2016 |
Est. primary completion date | February 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Patients with a positive skin prick test to grass pollen and with pollen allergic symptoms during the pollen season OR patients with a negative skin prick test and with no allergic symptoms during the pollen season. - Age > 18 and < 50 years - Written informed consent - Willingness to adhere to visit schedules - Adequate contraceptive precautions in female patients with childbearing potential Exclusion Criteria: - Current or recent (finished less than 2 years) immunotherapy against grass pollen. - Systemic steroid treatment less than 6 weeks before the inclusion in the study. - Nasal steroid spray, oral leukotriene antagonists or long-acting antihistamines less than 4 weeks before the inclusion. - Presence of purulent secretions in nasal cavity. - Severe septal deviation (septum reaching concha inferior or lateral nasal wall). - Patient is pregnant or breastfeeding. - Patient has any disorder of which the investigators feel at the time of evaluation for participation in the study that this may compromise the ability to give truly informed consent for participation in this study. - Patient is currently enrolled in other investigational drug trial(s) or is receiving other investigational agent(s) for any other medical condition. - No independent medication management in daily life or disability to perform fine motoric handling of medication - Patients with asthma will be excluded. - Patients suffering from claustrophobia |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science
Country | Name | City | State |
---|---|---|---|
Belgium | uz leuven ORL | Leuven | Vlaams Brabant |
Lead Sponsor | Collaborator |
---|---|
Universitaire Ziekenhuizen Leuven |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | brain activation | The specific aim of this study is to visualize the type and location of brain activation in healthy and allergic volunteers by a nasal provocation with histamine, using the functional MRI technology. | 5 minutes | No |
Secondary | nasal symptoms and Peak Nasal Inspiratory Flow | Evaluation of nasal symptoms (runny nose, blocked nose, itchy nose and post-nasal drip) and conjunctival symptoms (lacrimation and itchy eyes) will be done with VAS scores and the Peak Nasal Inspiratory Flow (PNIF) will be measured before and after both functional MRI (fMRI) scans | before and after scans | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02443805 -
Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR
|
Phase 3 | |
Completed |
NCT03094845 -
Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients
|
Phase 2 | |
Completed |
NCT01923792 -
ToleroMune House Dust Mite Follow on Study
|
N/A | |
Completed |
NCT01930461 -
Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma
|
Phase 2 | |
Completed |
NCT00574704 -
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
|
Phase 2 | |
Completed |
NCT00263549 -
Safety and Efficacy of House Dust Mite Allergen Extract in the Treatment of Allergic Rhinoconjunctivitis
|
Phase 4 | |
Completed |
NCT05019209 -
Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients
|
N/A | |
Recruiting |
NCT02238353 -
AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR)
|
Phase 4 | |
Completed |
NCT01454544 -
A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet
|
Phase 3 | |
Completed |
NCT00574223 -
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
|
Phase 2 | |
Completed |
NCT02345278 -
SUBLIVAC FIX Mite Mixture Dose Tolerability Study
|
Phase 1/Phase 2 | |
Completed |
NCT01608243 -
Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts
|
Phase 1 | |
Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
Completed |
NCT01134757 -
Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction.
|
N/A | |
Recruiting |
NCT05395689 -
Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM
|
Phase 3 | |
Not yet recruiting |
NCT05400811 -
Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis
|
Phase 3 | |
Not yet recruiting |
NCT05450289 -
The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy
|
N/A | |
Recruiting |
NCT05174689 -
Epigenetic Regulation of Exercise Induced Asthma
|
N/A | |
Terminated |
NCT04874714 -
Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis
|
Phase 3 | |
Completed |
NCT00380926 -
Fish Oil and Asthma in House Dust Mite Allergy
|
Phase 2/Phase 3 |